Standard BioTools Q2 revenue falls on consumables weakness

Standard BioTools

05/08/2026 21:36

Overview
U.S. life science tools firm's Q2 revenue fell 8% yr/yr amid weaker consumables demand
Adjusted EBITDA loss for Q2 narrowed 84% yr/yr, reflecting cost discipline and restructuring
Company progressing toward Treeline Biosciences merger; full-year revenue outlook withdrawn

Outlook
Company is withdrawing its full-year 2026 revenue outlook due to pending merger with Treeline Biosciences
Standard BioTools expects to close Treeline Biosciences merger before year-end 2026

Result Drivers
CONSUMABLES WEAKNESS - Co said consumables revenue declined 10% yr/yr due to strong prior year and continued US Academia spend uncertainty
CAPITAL CONSTRAINTS - Instrument revenue fell 2% yr/yr, with co citing impact from capital-constrained end-markets
COST DISCIPLINE - Non-GAAP operating expenses fell 50% yr/yr, largely due to previously announced restructuring actions

Company press release: ID:nGNX1cd41T

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$20.10 mln
 
Q2 Loss Per Share
 
$0.07
 
Q2 Net Loss
 
$26.76 mln
 
Q2 Adjusted EBITDA
 
-$2.50 mln
 
Q2 Gross Margin
 
52.40%
 
Q2 Adjusted Gross Margin
 
56.30%
 
Q2 Operating Income
 
-$25.40 mln
 
Q2 Pretax Loss
 
$21.44 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Standard BioTools Inc. is $1.55, about 88.9% above its August 4 closing price of $0.82

Reuters Recommended Reads
Aug 5 - Charles River lifts profit forecast on improving biotech demand
Aug 4 - Waters lifts annual forecasts on strong lab-equipment and diagnostics demand
Aug 4 - Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)